Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.

Cardiovascular toxicology - 20 Sept 2026

Szubińska-Bałaban Paulina, Klotzka Aneta, Ziółkowska Katarzyna, Marciniak-Stępak Patrycja, Niedzielska Julia, Russo Federico, Suleiman Amro Abu, Glista Filip, Kuczmarska Angelika, Bukowska-Olech Ewelina

Abstract excerpt

Cancer therapy-related cardiovascular toxicity (CTR-CVT) is an umbrella term for myocardial, vascular, electrical, and inflammatory complications of cytotoxic, targeted, immune, and radiation-based therapies. Cancer therapy-related cardiac dysfunction (CTRCD) is used here more narrowly for treatment-related myocardial dysfunction, typically identified by changes in left ventricular ejection fraction, global...

Read the complete abstract on PubMed

Topics

Cardiotoxicity
Humans
Heart Disease Risk Factors
Genetic Predisposition to Disease
Pharmacogenomic Variants

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Animals

Antineoplastic Agents

Cardiovascular Diseases

Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42763821
DOI: 10.1007/s12012-026-10191-y
PMCID: PMC13590445

Genes

ERBB2
ERBB4
NRG1
TOP2B

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.PMID 42763821Read ↗

Doxorubicin-Induced Cardiotoxicity in Breast Cancer: Mechanistic Pathways, Pharmacogenomic Modifiers, and Translational Strategies.Semantic proximity Read ↗

Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stressSemantic proximity Read ↗

Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologistSemantic proximity Read ↗

Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity Read ↗

Heart Failure in Relation to Anthracyclines and Other Chemotherapies.Semantic proximity Read ↗

Epigenetic Changes Associated With Anthracycline‐Induced CardiotoxicitySemantic proximity Read ↗

Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.Semantic proximity Read ↗

Genetic Background in Patients with Cancer Therapy-Induced CardiomyopathySemantic proximity Read ↗

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Semantic proximity Read ↗

Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profilingSemantic proximity Read ↗

The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.Semantic proximity Read ↗

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.